We are constantly seeking participants for a number of studies. Please apply to any studies for which you may qualify, or call us at (417) 883-7889 for more information!
Clinvest is seeking volunteers with Type 2 Diabetes. This phase 3 study is evaluating the safety and efficacy of investigational study drug versus Semaglutide as a once weekly add-on injection therapy to metformin in patients with Type 2 Diabetes. Eligible participants need to have an HbA1c between 7%-10.5% and be on a stable dose of at least 1500 mg of metformin per day. The study will have 12 office visits over approximately 47 weeks. Your first appointment would last approximately 2 hours with follow-up visits lasting around 1 hour. Study medication, and diabetes testing supplies would be provided, as well as all study-related procedures, at no cost to you (including basic study-related physical exams, bloodwork, HbA1c, ECG’s, and urine drug/pregnancy tests). Compensation will be provided for your time and travel.
Dr. True and Clinvest are seeking volunteers with Episodic Migraines in the Springfield area. The purpose of this research study is to evaluate the safety and efficacy of the investigational drug, Atogepant. Qualified volunteers, who have previously taken an oral migraine preventative medication, will be randomly assigned to receive investigational drug or Placebo. Completion of the study would involve coming into the office for 8 appointments over a 16-week period. Your first appointment will last approximately 2 hours. You will be asked to come into the office 4 weeks following screening and every 2 weeks for the duration of the 16-week study. A safety follow-up visit will occur 4 weeks after your last dose. At the completion of the study, participants will have the option to continue in a 40 week Open-Label study where active medication will be provided.
The purpose of this study is to evaluate the efficacy and safety of risankizumab 150 mg for the potential treatment of signs and symptoms of psoriatic arthritis (PsA) in subjects with moderately to severely active PsA who do not respond to treatment after at least 12 weeks of therapy or for subjects who cannot take 1 or more conventional synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARD) or biologic therapies. The study is up to 233 weeks, 26 visits.
Eligible subjects over 50 years in age who have been newly diagnosed or have relapsing Giant Cell Arteritis. Participants will be randomized to receive either standard of care or investigational product in addition to standard of care for up to two years over 21 visits. Your first appointment would last approximately 2 hours. If you qualify and choose to volunteer, we would provide investigational study pills, or standard of care pills and all study-related procedures at no cost to you (including basic study-related physical exams, bloodwork, ECG’s, and urine drug/pregnancy tests). Compensation may be provided for your time and travel.
Eligible subjects ages 18-65 will come to our office for 3 visits over 13 weeks and treat one migraine attack at home with investigational product. Your first appointment would last approximately 2 hours. If you qualify and choose to volunteer, we would provide an investigational study pill and all study-related procedures at no cost to you (including basic study-related physical exams, bloodwork, ECG’s, and urine drug/pregnancy tests). You will be asked to complete a detailed diary about your treated migraine attack. Compensation will be provided for your time and travel.
This study consists of 5 in-person visits and 1 phone call over 16 weeks. Qualified people who report 8-20 headaches per month will be randomized to use non-invasive vagus nerve stimulation delivered through an investigational device 3 times a day during a 12-week treatment phase. Your first appointment would last approximately 2 hours. If you qualify and choose to volunteer, we would provide the study device and all study-related procedures at no cost to you. You would be asked to use an electronic diary to answer daily questions about your headaches for the entire duration of the study. You would also be asked to fill out more detailed questionnaires during the appointments. Compensation will be provided for your time and travel.
The purpose of this study is to determine the benefit of taking 300mg of an investigational drug compared to the currently approved 150mg dose for patients with Ankylosing Spondylitis (AS). Qualifying volunteers would come to our office for approximately 19 visits over a 52-week period. Patients will be given 16 doses of the investigational drug during the course of the study.
This research study is to compare the duration, safety, and effectiveness of the investigational study medication (Fremanezumab) to placebo (an inactive look-alike). Qualified volunteers will be randomly assigned to receive study medication or placebo. Completion of the study would involve coming to our office for 7 appointments, over a 44-week period. Subjects will receive 3 doses of investigational product or placebo during the study.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 20 Week Study of the Efficacy and Safety of the Tx360® Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine.